75%Confidence
0Views
FDASource
2026-03-21Date
Summary
Midodrine Hydrochloride Tablets recall due to defective blister packaging reveals potential packaging integrity issues at Major Pharmaceuticals that could compromise drug stability. This may affect patient access to this blood pressure medication and trigger additional packaging quality reviews across the distributor's product lines.
Actionable: Verify packaging integrity for critical medications and consider dual-sourcing strategies for essential cardiovascular drugs.
AI Confidence: 75%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now